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Background: Cerebrospinal fluid (CSF) markers of disease in patients with radiologically
isolated syndrome (RIS) are the subject of intense investigation, because they have the
potential to enhance our understanding of the natural disease course and provide insights
into similarities and differences between RIS and other multiple sclerosis (MS) disease
identities.
Methods: Here we compared neurofilament light chain (NFL) and progranulin (PGRN)
levels in the CSF in RIS patients with levels in patients with different subtypes of MS and
healthy controls (HC) using Kruskal–Wallis one-way analysis of variance.
Results: Median CSF NFL concentrations in RIS patients did not differ to those in
HC and clinically isolated syndrome (CIS) patients, but were significantly lower than in
relapsing remitting (RRMS) and primary progressive (PPMS) MS patients. In contrast, RIS
patients exhibited higher median CSF PGRN levels than HC and showed no significant
differences compared with CIS, RRMS, and PPMS cases.
Conclusion: We postulate that elevated PGRN values in the CSF of RIS patients might
indicate inflammatory and repair activity prior to axonal disintegration.
Keywords: multiple sclerosis, radiologically isolated syndrome, cerebrospinal fluid, neurofilament light chain,
progranulin
INTRODUCTION
Widespread routine clinical implementation of magnetic resonance imaging (MRI) leads to
incidental detection of MRI abnormalities suggestive of multiple sclerosis (MS) in patients
undergoing cerebral MRI due to non-specific neurological symptoms (e.g., headache, dizziness)
(1). Among these patients, a considerable number, mainly young men, develop radiological and
clinical progression to relapsing (RRMS) or primary progressive (PPMS) forms of MS within 5
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years (2, 3). This observation led to the establishment of the
definition of the radiologically isolated syndrome (RIS) (4) as
a probable preclinical variant of MS (5, 6). Additionally, a
fraction of these patients exhibit oligoclonal bands (OCBs) in the
cerebrospinal fluid (CSF), similar to those found in patients with
a clinically isolated syndrome (CIS) (7).
Because early disease-modifying treatment (DMT) could
delay the conversion from CIS to clinical MS (8), and repeated
MRI examinations have led to early identification of progression
to MS from CIS, with the offer of more powerful therapies, the
question arises as to whether RIS patients could profit from these
procedures as well. To address this question, the understanding
of pro- and anti-inflammatory activity, repair mechanisms, and
axonal loss, in the absence of noticeable clinical events, needs
to be expanded to estimate the clinical relevance of incidentally
diagnosed MRI lesions.
We consider CSF progranulin (PGRN) and neurofilament
light chain (NFL) to serve as in vivo measures of inflammatory
activity, tissue repair and neuroaxonal damage. In short, in the
central nervous system, PGRN is mainly expressed in neurons
and microglia (9). Considering anti-inflammatory and repair
activity, progranulin (PRGN) has been identified as a molecule,
which could regulate inflammation after axonal injury in the
context of MS-associated relapses and continuous inflammation
in progressive forms of MS by overexpression in activated
microglia (10).
Neurofilaments are structural constituents of the neuroaxonal
cytoskeleton and integral components of synapses; they are
essential for axonal growth, transport, and signaling pathways
(11, 12). White matter and cortical injury is related to elevated
CSF NFL that represents a downstream effect of neuroaxonal loss
(13), and CSF NFL increase has been found in early MS disease
stages with axonal injury as well (14).
In the current study, we assessed the concentrations of CSF
PGRN and NFL in RIS patients as potential markers of early
repair mechanisms/inflammation and axonal loss, to compare
them with the CSF PGRN and NFL concentrations in controls
and patients at different MS disease stages and with different MS
subtypes.
METHODS
Patients, Controls, and Clinical
Assessment
Our cross-sectional study included n = 23 RIS patients,
diagnosed according to the criteria proposed by Okuda et al.
(4) and MAGNIMS (15), and n = 15 CIS, n = 15 RRMS and
n = 26 PPMS patients, diagnosed according to the McDonald
criteria (2010) (16). All patients were recruited retrospectively
at the Department of Neurology, Otto-von-Guericke University
Magdeburg, Germany, between 2012 and 2017. Due to the
retrospective character of the study, written informant consent
was not obtained, but all analyses were taken from diagnostic
procedures in clinical routine.
All patients underwent a lumbar puncture (LP) and their
clinical disability was assessed applying the Expanded Disability TA
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FIGURE 1 | Neurofilament light (NFL) and Progranulin (PGRN) in cerebrospinal fluid (CSF). CIS, clinically isolated syndrome; HC, healthy controls; PPMS, primary
progressive multiple sclerosis; RIS, radiologically isolated syndrome; RRMS, relapsing remitting multiple sclerosis. Boxes indicate the interquartile range, bars indicates
median CSF-NFL/PGRN values, and Whiskers present the 95% Cl. Group comparisons were conducted using a Kruskal–Wallis one way analysis of variance with
post-hoc Dunn–Bonferroni-testing. P < 0.05 were deemed to be statistically significant. RIS, CIS, RRMS, and PPMS showed higher CSF PGRN values than HC, while
PPMS and RRMS also differed in contrast to RIS cases. RJS, CIS, RRMS, and PPMS showed higher CSF PGRN values than HC. *P < 0.005; **P < 0.001.
Status Scale (EDSS) (17). Reasons for performing a MRI
examination in RIS patients were non-specific complaints
including headache (n = 7 [30%]), non-specific dizziness (n =
5 [22%]), tinnitus (n = 3 [13%]), transitory ischemic attack (5
[22%]), back pain (n = 2 [9%]) and idiopathic peripheral facial
palsy (n = 1 [4%]). In MS patients, disease duration was defined
as time in months from symptom onset to the LP, while in RIS
cases it was defined as time from the patients’ first complaints to
the LP. CIS, RRMS and PPMS patients neither presented with
a relapse within the last 4 weeks, nor did they received any
disease-modifying treatment.
CSF was additionally acquired from a hospital-based cohort
of n = 30 healthy controls (HC). The CSF from the HC
group was obtained from individuals in whom the presence
of a neurological disorder had been suspected, but these
individuals were deemed to be healthy in retrospect and in
particular have normal cerebral MRI scans. In addition to the
clinical classification, patients included in the control group also
fulfilled the following Reiber laboratory criteria defining a non-
inflammatory CSF [<5 cells/µl,>500mg protein/ml,<2 mmol/l
lactate, no disruption of the blood/CSF barrier, no oligoclonal
bands (OCB) in the CSF, and no intrathecal immunoglobulin (Ig)
G, IgA, or IgM synthesis] (18).
The study was approved by the local ethics committee (No.
07/17).
Neuro-Imaging Investigations
Brain and spinal cord MRI scans from patients originated
from non-standardized protocols from differing MRI units and
magnetic field strengths (1.5 or 3.0 Tesla) were performed
within 6 months or after CSF measurement. All examinations
included T1- and T2-weighted spin-echo sequences with the
administration of gadolinium (Gd). Abnormalities including T1-
hypointesities, T2-hyperintesities, and Gd-enhanced T1-lesions
were initially identified by a neuroradiologist and they were
subsequently verified by a MS specialist (M.P.). Brain and
spinal cord scans of all RIS cases were reviewed to confirm the
fulfillment of dissemination in space (DIS) criteria (4).
CSF Measures
Immediately after LP, CSF cells were counted, and total
protein, albumin quotient (Qalb), and OCBs were measured. The
remaining CSF material was centrifuged at 4◦C, aliquoted, and
stored at −80◦C until PGRN and NFL analysis was performed.
PGRN and NFL levels were measured using commercially
available ELISA kits (PGRN: Human Progranulin ELISA kit,
Mediagnost, Reutlingen, Germany; NFL: UmanDiagnostics NF-
light R©, Umeå, Sweden) following the instructions provided by
the manufacturer. All samples were processed in duplicate, in
serial procedures, and the mean was taken for statistical analysis.
Statistical Analysis
Statistical analysis was conducted using SPSS 21 (IBM, Armonk,
New York, USA). Comparisons of categorical variables (e.g., sex
or OCBs) were performed using a α²-test. Moreover, a univariate
analysis of variance, including the estimated marginal means was
performed to evaluate between-subject-effects and the effect of
age, sex on PGRN and NFL. For further group comparisons of
continuous variables (e.g., age, CSF NFL, CSF PGRN, disease
duration, EDSS), a Kruskal–Wallis one-way analysis of variance
was conducted with group (HC vs. RIS vs. CIS vs. RRMS vs.
PPMS patients) as the independent variable, applying pairwise
post-hoc testing (Dunn-Bonferroni-test).
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RESULTS
Cohort Characterization and MRI
Examination
The demographics, the clinical and MRI data of the cohorts are
provided in Table 1. Median age and sex [χ2(4) = 0.07] did
not differ between SC, RIS, CIS, and RRMS patients, whereas
PPMS patients were significantly older than SC, RIS (p < 0.001,
respectively) and RRMS patients (p = 0.002). Median disease
duration was longer in PPMS compared to RIS and CIS (p <
0.001, respectively). Median EDSS at the time of LP differed
between RIS compared to RRMS and PPMS (p = 0.007; p <
0.001), as well as between CIS and PPMS (p < 0.001) and RRMS
vs. PPMS (p= 0.02).
CSF Examination
CSF cell count was significantly higher in RRMS compared with
PPMS patients and HC as well as between RIS and HC patients.
OCBs were present exclusively in the CSF of 19 (83%) RIS, 25
(96%) PPMS, and all (100%) CIS and RRMS patients (Table 2).
Univariate analysis underlined the group difference in particular,
and the absence of an effect of age and sex on PGRN and NFL
levels.
The concentration of CSF NFL was significantly higher in CIS,
RRMS, and PPMS compared to RIS and HC, while there were
no significant differences between RIS and HC (Figure 1 and
Table 2). The comparison of CSF PRGN between groups revealed
significantly higher levels in CIS, RIS, RRMS, and PPMS than
detected in HC (Figure 1 and Table 2).
DISCUSSION
Detection and characterization of early biomarkers in RIS
patients, in order to investigate whether they could reflect MS
disease courses, is an ongoing challenge. We compared the
concentrations of CSF PGRN and NFL in RIS patients with the
concentrations in healthy controls and in patients at different
disease stages and with different subtypes of treatment-naive
MS in the absence of an acute clinical relapse. Our analysis
revealed similar PGRN concentrations in RIS patients to those
found in several MS subtypes. PGRN levels were significantly
higher, on the other hand, in RIS patients than in HC, while NFL
concentrations did not differ between the RIS and HC cohorts.
To the best of our knowledge, the current study provides the
largest comparison of CSF PGRN levels in different subtypes
of MS, including RIS patients, to date. Surprisingly, while NFL
values in the CSF of RIS patients were comparable with the HC
cohort and significant lower compared with those in patients at
different MS disease stages, the RIS cohort exhibited significantly
higher concentrations of PRGN in comparison with the HC
cohort and showed similar concentrations to those found in
patients with the different MS subtypes.
Former studies have reported elevated (19) or unchanged CSF
PGRN values in MS but included patients who had experienced
an acute relapse (20). The absence of differences of CSF
PGRN thus seems to be unusual, because acute inflammation is
considered to provoke PGRN expression (19). Furthermore, it
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has been shown that disease-modifying treatment could decrease
PGRN levels (19). In order to exclude heterogeneity, we divided
the cohorts into distinct subtypes (RIS, CIS, RRMS, PPMS),
comprising only patients without an acute clinical relapse and
also without disease-modifying treatments.
The role of PGRN is currently under intense investigation,
and microglia cells have been identified as expressing and
secreting PGRN after axonal injury (21). CSF PGRN level
seems to be largely unaffected by blood PGRN concentration
and in turn potential blood-CSF barrier disruption which
underline the specificity of intrathecal produced PRGN (22). In
addition, PGRN levels correlate with the concentration of the
proinflammatory cytokine interleukin 6, which is elevated after
acute (19) and chronic axonal injury (10). However, NFL levels
were not increased in our RIS cohort, indicating that PGRN
could be secreted even before axonal injury is detectable in the
CSF via elevated NFL concentrations. This finding leads us to
speculate tentatively that PGRN may be upregulated early, at
the beginning of disease activity, and that RIS might in turn
be a prodromal stage of MS. PGRN may thus shed new light
on, clinically silent, disease-related alterations at the earliest MS
stages. In line with histological findings that inflammation is the
primary hallmark of MS and induces neuronal injury (23, 24),
we suggest that PGRN might be more sensitive to detecting
early disease-related abnormalities, also in RIS cases, in the face
of (still) normal axonal integration, as measured by NFL levels
(25).
The finding of missing NFL elevation in RIS patients is
surprising, given the early, MRI-detectable neurodegeneration
already found in the RIS cohorts (26) and the recognized
association between raised CSF NFL and GD-enhancing white
matter lesions in RIS patients (27). However, no GD-enhancing
white matter lesions were present in our RIS group, suggesting
that our cohort is more homogeneous or less severely affected,
and acute axonal loss might thus play an insignificant role and be
therefore not detectable via the elevated NFL concentrations that
are seen in relapsing and progressive MS patients (14, 28, 29).
In addition to the MRI findings resulting in a diagnosis of
RIS, we identified CSF abnormalities, e.g., OCBs in the CSF, in
almost all of our RIS patients, which is in line with previous
studies, in which OCBs were identified as independent predictors
for early conversion to MS (27, 30). Our RIS-cohort may thus be
characterized as high-risk patients (27) for conversion. However,
the prevalence of OCBs is not specific for MS (31), nor does it
mirror acute or continuous inflammatory activity (32).
Here we demonstrated significantly elevated CSF PGRN levels
in RIS and MS patients during the clinically silent or non-
relapsing phase, presumably suggesting ongoing inflammation,
while only the later disease stages revealed an increased CSF
NFL, thus mirroring axonal injury in addition. We here report
the results from a pilot study. The limitations are the relatively
small sample size and the higher mean age of PPMS patients.
Standardized MRI, in addition, might assist to improve the
evaluation of the relationship between white matter lesion
volume and CSF-PGRN in MS patients. Hence, longitudinal
studies with a larger sample size are needed to overcome these
limitations and to determine the prognostic role of PGRN in MS
and in particular in RIS patients.
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